Budesonide ER Capsules
ID: SPE2D2-25-R-0008Type: Solicitation
Overview

Buyer

DEPT OF DEFENSEDEFENSE LOGISTICS AGENCYDLA TROOP SUPPORTPHILADELPHIA, PA, 19111, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/79a053549f084ec385b255f43dbe0911/view
Timeline
  1. 1
    Posted Mar 31, 2025, 12:00 AM UTC
  2. 2
    Updated Mar 31, 2025, 12:00 AM UTC
  3. 3
    Due Apr 30, 2025, 7:00 PM UTC
Description

The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is soliciting proposals for the procurement of Budesonide ER 3MG Capsules, as outlined in Solicitation No. SPE2D225R0008. This solicitation requires electronic submission of offers via the Defense Logistics Agency Internet Bid Board System (DIBBS) and includes a comprehensive Statement of Work detailing contract obligations such as delivery schedules, product registration, and compliance with federal acquisition regulations. The procurement of these pharmaceutical products is critical for supporting military health needs, ensuring that service members have access to necessary medications. Interested vendors should direct inquiries to Christopher Newman at christopher.newman@dla.mil or Jason Wray at jason.wray@dla.mil, with proposals due by the specified deadline in the solicitation document.

Files
Title
Posted
Budesonide ER SPE2D225R0008 Solicitation.pdf
Mar 31, 2025, 9:05 PM UTC
The document outlines Solicitation No. SPE2D2-24-R-0013, which pertains to a federal request for proposals (RFP) for the procurement of pharmaceutical products, specifically Budesonide ER 3MG Capsules. It details submission instructions for offers via the Defense Logistics Agency Internet Bid Board System (DIBBS), emphasizing the necessity of electronic proposals. The solicitation includes a comprehensive Statement of Work, specifying contract obligations including delivery schedules, product registration, labeling requirements, and compliance with various federal acquisition regulations. The document highlights critical contract clauses such as FAR 52.212-4 regarding terms and conditions for commercial items, and DFARS clauses prohibiting certain telecommunications equipment from covered foreign countries. It also mandates the submission of a subcontracting plan for large businesses and outlines a reporting system for contractor performance evaluations. Furthermore, the RFP includes stipulations for compliance with federal laws concerning ethics, labor standards, and trade agreements. Overall, the solicitation aims to ensure accountability and integrity while promoting compliance with federal guidelines in the acquisition processes for pharmaceutical supplies, reinforcing the government’s commitment to ethical procurement practices.
Lifecycle
Title
Type
Budesonide ER Capsules
Currently viewing
Solicitation
Budesonide ER Capsules
Presolicitation
Similar Opportunities
Rabeprazole Sodium DR
Buyer not available
The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is soliciting proposals for the supply of Rabeprazole Sodium DR 20MG Tablets. This procurement aims to fulfill the pharmaceutical needs of military personnel, emphasizing compliance with federal acquisition regulations and ethical conduct in contractor performance. Interested vendors must submit their proposals via the DLA's Internet Bid Board System (DIBBS) by May 15, 2025, and are encouraged to reach out to primary contact Trong Nguyen at Trong.Nguyen@dla.mil or secondary contact Jason Wray at jason.wray@dla.mil for further inquiries.
Dextroamphetamine - Amphetamine ER
Buyer not available
The Defense Logistics Agency (DLA) is preparing to issue a solicitation for a national requirements contract for Dextroamphetamine - Amphetamine ER Capsules, specifically in dosages of 5 MG, 10 MG, 15 MG, 20 MG, 25 MG, and 30 MG, packaged in 100 count bottles. This procurement aims to establish a national supply source for these pharmaceutical products, which will be utilized by the Department of Defense, Bureau of Prisons, and Indian Health Service customers through DLA and VA prime vendor programs. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, and it is expected to be solicited as a commercial item under FAR part 12. Interested parties should monitor the DLA Bid Board System (DIBBS) and SAM.gov for the solicitation, projected for April 2025, and can direct inquiries to Nancy Fernandez at nancy.fernandez@dla.mil or Jason Wray at jason.wray@dla.mil.
Dimethyl Fumarate DR Presolicitation
Buyer not available
The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.
Duloxetine HCL DR Capsules
Buyer not available
The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Duloxetine HCL DR Capsules, which includes various dosages and packaging options. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are critical for the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options, and is expected to be solicited in April 2025. Interested parties should direct inquiries to Christopher Newman at christopher.newman@dla.mil or 445-737-7371, and are encouraged to monitor the DLA Bid Board System and Sam.Gov for updates.
Pantoprazole DR Tablets
Buyer not available
Presolicitation DEPT OF DEFENSE Pantoprazole DR Tablets: The Defense Logistics Agency is planning to issue a national requirements contract for Pantoprazole DR Tablets. These tablets, available in 20MG and 40MG strengths, will be provided in 90 and 1000 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The tablets will be purchased by the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. The annual usage estimates will be provided in the solicitation. Interested parties can find more information on the DLA Bid Board System and Beta Sam.Gov websites. The solicitation is projected to be issued in September 2021.
Solifenacin
Buyer not available
The Defense Logistics Agency (DLA) is preparing to issue a solicitation for a national requirements contract for Solifenacin, specifically 5MG and 10MG tablets in 30 and 90 count bottles. This procurement aims to establish a national supply source for these pharmaceutical products, which will be utilized by the Department of Defense, Indian Health Service, and Bureau of Prisons through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, and it is expected to be fully competitive and unrestricted. Interested parties should direct inquiries to Jayne Do at jayne.do@dla.mil, with the solicitation anticipated to be posted in April 2025 on the DLA Bid Board System and SAM.gov.
Pyridostigmine Bromide Tablets
Buyer not available
The Defense Logistics Agency (DLA) Troop Support is seeking sources capable of providing Pyridostigmine Bromide Tablets (PB Tabs), specifically the USP 30 MG formulation, in compliance with FDA specifications. The procurement involves an estimated annual requirement of 27,000 packages, with each package containing 210 individually sealed tablets, and deliveries will be made to the Defense Distribution Center in Norfolk, VA. Pyridostigmine Bromide Tablets are critical for military use, and the contract will include a base year with four one-year option periods, allowing for adjustments based on service requirements. Interested vendors should submit their responses electronically to Contracting Specialist Rosbert Jones at rosbert.jones@dla.mil, ensuring all information remains confidential as per federal regulations.
Morphine IR & ER
Buyer not available
The Defense Logistics Agency (DLA) is preparing to issue a solicitation for a national requirements contract for Morphine Immediate Release (IR) and Extended Release (ER) Tablets. The procurement will include Morphine IR in 15MG and 30MG in 100 count bottles, as well as Morphine ER in 15MG, 30MG, and 60MG in 100 count bottles, aimed at establishing a national supply source for the Department of Defense, Indian Health Service, and Bureau of Prisons customers. This contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options, and it will be solicited as a commercial item under FAR part 12. Interested parties should contact Christopher Newman at 445-737-7371 or christopher.newman@dla.mil for inquiries, and they are encouraged to monitor the DLA Bid Board System (DIBBS) and Sam.Gov for updates, with the projected solicitation date set for April 2025.
Fluticasone Propionate
Buyer not available
The Defense Logistics Agency (DLA) is preparing to issue a solicitation for a national requirements contract for Fluticasone Propionate, a pharmaceutical product essential for respiratory treatments. The procurement will include various formulations of Fluticasone Propionate combined with Salmeterol, specifically in HFA inhalers, and aims to establish a national supply source for the Department of Defense, Indian Health Service, and Bureau of Prisons customers. This unrestricted and fully competitive acquisition will be a firm-fixed price contract with a one-year base period and four one-year options, with the solicitation expected to be posted in May 2025. Interested parties can direct inquiries to Jeremy Brown at jeremy.brown@dla.mil or call 445-737-5419, and are encouraged to set up automated notifications for updates on the solicitation.
Rabeprazole Sodium Delayed Release Tablets
Buyer not available
Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Rabeprazole Sodium Delayed Release Tablets. The tablets will be used for medical purposes and will be available in 30, 90, and 500 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source to provide the tablets for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. Interested parties should contact Phyllis Daraio for more information. The projected solicitation date is February 2020.